Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, OntarioDr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.
Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.
Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.
Disclosures
- Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics
Recent Contributions to PracticeUpdate:
- Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban
- Concomitant Use of Selective Serotonin Reuptake Inhibitors With OACs and Risk of Major Bleeding
- Development of a Target Concentration Intervention to Individualize Paroxysmal Nocturnal Hemoglobinuria Treatment With Pegcetacoplan
- Real-World Experience of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria
- Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab
- Association of Glycaemic Index and Glycaemic Load With Risk of Type 2 Diabetes
- Association of Intake of SGLT2 Inhibitors With Functional Capacity and Quality of Life in Patients With Heart Failure
- Dosing Patterns of Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab in the US
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
- Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria: Use, Clinical Effectiveness, and Influence on HRQoL and Productivity